​

Pacira BioSciences (PCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PCRX Stock Forecast

Pacira BioSciences (PCRX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $18.33, with a high of $25.00 and a low of $12.00. This represents a -29.58% decline from the last price of $26.03.

$10 $15 $20 $25 $30 $35 High: $25 Avg: $18.33 Low: $12 Last Closed Price: $26.03

PCRX Stock Rating

Pacira BioSciences stock's rating consensus is Hold, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (33.33%), 6 Hold (66.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 9 0 6 3 Strong Sell Sell Hold Buy Strong Buy

PCRX Forecast vs Benchmarks

TypeNameUpside
StockPacira BioSciences-29.58%
SectorHealthcare Stocks 25.20%
IndustrySpecialty & Generic Drug Manufacturers Stocks24.78%

Price Target Trends

1M3M12M
# Anlaysts127
Avg Price Target$25.00$18.50$28.29
Last Closing Price$26.03$26.03$26.03
Upside/Downside-3.96%-28.93%8.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25214119
Dec, 24214119
Nov, 243751117
Oct, 243752118
Sep, 243752118
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 30, 2025Les SulewskiTruist Financial$25.00$26.03-3.96%-3.96%
Nov 07, 2024David AmsellemPiper Sandler$12.00$17.37-30.92%-53.90%
Sep 24, 2024Glen SantangeloJefferies$18.00$14.7721.87%-30.85%
Aug 13, 2024Les SulewskiTruist Financial$8.00$12.29-34.91%-69.27%
Jul 02, 2024Oren LivnatH.C. Wainwright$57.00$21.91160.16%118.98%
Jun 13, 2024Glen SantangeloJefferies$36.00$28.5026.32%38.30%
May 21, 2024David AmsellemPiper Sandler$42.00$30.6836.90%61.35%
Jan 06, 2023BMO Capital$52.00$38.5035.06%99.77%
Jan 06, 2023Needham$63.00$38.5063.64%142.03%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 07, 2024Piper SandlerNeutralNeutralhold
Sep 24, 2024Truist FinancialSector PerformSector Performhold
Sep 24, 2024JefferiesBuyBuyhold
Aug 12, 2024RBC CapitalSector PerformSector Performhold
Aug 12, 2024RBC CapitalUnderperformSector Performdowngrade
Aug 12, 2024Raymond JamesUnderperformMarket Performdowngrade
Aug 12, 2024Piper SandlerBuyNeutraldowngrade
Jul 25, 2024Piper SandlerBuyBuyhold
Jul 03, 2024BarclaysEqual-Weightdowngrade

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.41$0.95$0.35$0.81-----
Avg Forecast$2.14$2.91$2.63$2.91$3.13$3.29$3.72$4.23$4.66
High Forecast$1.66$2.26$1.91$2.78$3.00$2.73$2.02$1.76$3.34
Low Forecast$2.43$3.30$3.01$3.02$3.39$3.92$5.35$6.29$5.89
Surprise %59.35%-67.35%-86.69%-72.16%-----

Revenue Forecast

$350M $490M $630M $770M $910M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$420.83M$541.53M$666.82M$674.98M-----
Avg Forecast$430.43M$536.73M$666.80M$674.23M$696.42M$715.50M$757.03M$776.28M$836.93M
High Forecast$355.94M$443.84M$526.79M$673.31M$674.92M$564.23M$757.01M$607.29M$654.74M
Low Forecast$474.19M$591.28M$740.69M$674.89M$777.84M$930.36M$757.05M$934.96M$1.01B
Surprise %-2.23%0.90%0.00%0.11%-----

Net Income Forecast

$0 $70M $140M $210M $280M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$145.52M$41.98M$15.91M$41.95M-----
Avg Forecast$135.29M$38.43M$46.47M$41.95M$165.98M$172.79M$191.65M$209.41M$241.96M
High Forecast$106.29M$28.85M$35.09M$31.68M$156.01M$141.97M$105.08M$91.63M$173.49M
Low Forecast$164.28M$48.01M$57.84M$52.23M$175.95M$203.60M$278.22M$327.18M$306.26M
Surprise %7.57%9.24%-65.76%------

PCRX Forecast FAQ

Is Pacira BioSciences stock a buy?

Pacira BioSciences stock has a consensus rating of Hold, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Pacira BioSciences is a neutral investment for most analysts.

What is Pacira BioSciences's price target?

Pacira BioSciences's price target, set by 9 Wall Street analysts, averages $18.33 over the next 12 months. The price target range spans from $12 at the low end to $25 at the high end, suggesting a potential -29.58% change from the previous close price of $26.03.

How does Pacira BioSciences stock forecast compare to the average forecast of its sector, industry, and investment themes?

Pacira BioSciences stock forecast shows a -29.58% downside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the specialty & generic drug manufacturers stocks industry (24.78%).

What is the breakdown of analyst ratings for Pacira BioSciences over the past three months?

  • January 2025: 22.22% Strong Buy, 11.11% Buy, 44.44% Hold, 11.11% Sell, 11.11% Strong Sell.
  • December 2024: 22.22% Strong Buy, 11.11% Buy, 44.44% Hold, 11.11% Sell, 11.11% Strong Sell.
  • November 2024: 17.65% Strong Buy, 41.18% Buy, 29.41% Hold, 5.88% Sell, 5.88% Strong Sell.

What is Pacira BioSciences’s EPS forecast?

Pacira BioSciences's average annual EPS forecast for its fiscal year ending in December is 3.13 for 2024, a 286.42% increase from the reported $0.81 in 2023. The prediction for 2025 is $3.29, $3.72 for 2026, $4.23 for 2027, and $4.66 for 2028.

What is Pacira BioSciences’s revenue forecast?

Pacira BioSciences's average annual revenue forecast for its fiscal year ending in December is $696.42M for 2024, a 3.18% increase from the reported $674.98M in 2023. The forecast for 2025 is $715.5M, $757.03M for 2026, $776.28M for 2027, and $836.93M for 2028.

What is Pacira BioSciences’s net income forecast?

For its fiscal year ending in December, Pacira BioSciences's average annual net income forecast is $165.98M for 2024, reflecting an 295.61% increase from the reported $41.96M in 2023. The projection for 2025 is $172.79M, $191.65M for 2026, $209.41M for 2027, and $241.96M for 2028.